PTC Therapeutics said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of fatal neurodegenerative disease called amyotrophic lateral sclerosis.
The 2024 Access to Medicine Index shows that some manufacturers are increasingly prioritising LMICs, but broader interest in equitable access is waning. Udani Samarasekera reports.